medigraphic.com
SPANISH

Salud Mental

ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2011, Number 2

<< Back Next >>

Salud Mental 2011; 34 (2)

Estudio preliminar de la expresión del mensaje genético del transportador de serotonina en células mononucleares de sangre periférica en pacientes con dependencia al alcohol con y sin depresión mayor comórbida

Becerril-Villanueva E, Moreno-Aguilar J, Mendieta-Cabrera D, González-Cruz D, Natera-Rey G, Pavón-Romero L, Hernández-Gutiérrez ME
Full text How to cite this article

Language: Spanish
References: 49
Page: 139-147
PDF size: 155.59 Kb.


Key words:

Alcohol-dependent, major depressive disorder, 5-TT, PBMC, RT-PCR.

ABSTRACT

The 2008 National Addiction Survey demonstrated the existence of 39 million alcohol drinkers, of whom 4.2 million are excessive drinkers and 4.8 million are alcohol dependents. No reports of the comorbidity of psychiatric disorders in alcohol consumers in our country exist. Nevertheless, 40% to 50% of alcohol-dependent patients from other countries have some sort of psychiatric disorder, such as major depression.
Serotonergic function is a key mediator of mood states, impulsiveness, and addictive behavior, including alcohol consumption. Several studies have noted alterations in the serotonergic system in alcoholics (as demonstrated by an increase in the shooting frequency of raphe nuclei serotonergic neurons, an increase in serotonin levels in the accumbens nuclei, and a loss in serotonergic neurons in the raphe nuclei) and depressed patients (decreases in the density of serotonin reuptake transporter [5-HTT] and serotonin levels [5-HT]).
Clinical studies have documented that excessive alcohol intake reduces 5-HT levels and that this condition potentiates psychiatric disorders, such as anxiety, major depression, and alcohol dependence. These data demonstrate an association between alcoholism, psychiatric disorders, and alcohol dependence.
By molecular biology techniques, genetic risk factors have been identified and candidate genes, such as 5-HTT, have been selected. This gene is associated with a greater susceptibility to onset of alcoholdependence and major depression.
The 5-HTT gene lies in the SLC6A4 locus of 17q11.1-q12 and encodes a 600-amino-acid integral membrane protein. This transporter regulates serotonergic neurotransmission through removal of 5-HT from the synaptic space. Pharmacological research has shown that selective reuptake inhibitors (5-HTT blockers) reduce alcohol intake in alcohol-dependent and major depression patients.
Serotonergic system receptors, such as 5-HTT, 5-HT1, and 5-HT2, are expressed in nervous system and immune system cells; thus it is likely that both systems have functional similarities. Due to this property, peripheral blood mononuclear cells (PBMCs) can be used to research neurodegenerative, psychiatric, and alcohol dependence disorders.
The aim of this study was to assess 5-HTT expression levels in the PBMCs from alcohol-dependent patients and patients with comorbid alcohol-dependence and major depression disorder.
Materials and methods: The Outpatient Consultative Service from the Centro de Ayuda a Alcohólicos y Familiares (CAAF) and the Centro de Alcohólicos y Drogadictos «Carrasco» screened 70 patients from February to November 2008. Twenty patients who met the criteria of alcohol dependence, according to the Spanish version of the Mini International Neuropsychiatric Interview (MINI), were accepted. Alcohol dependence was based on the Alcohol Dependence Scale (EDA) that was adapted to the Mexican population.
Healthy volunteers (n=12) were selected concurrently from the general population of Mexico City with the start of patient enrollment. A psychiatrist evaluated the mental health of these patients using MINI. Clinical and laboratory trials demonstrated normal standard reference values.
Patients were included based on INPRFNC092318.1 research protocol procedures, which were approved by the Ethics Committee of the Instituto Nacional de Psiquiatría Ramón de la Fuente.
All participants were given a detailed explanation concerning the study objectives and gave their signed informed consent.
The patients for this study were men and women, aged 18 years and older who presented a diagnosis of alcohol dependence. Patients were grouped as follows: Group A: diagnosed alcohol dependence (n=12) and Group B: diagnosed alcohol dependence depressed patients (n=12).
All patients arrived to the clinical laboratory from 8:00 to 9:00 a.m. to undergo a peripheral blood test. Blood was drawn by venous puncture and placed into anticoagulant-coated tubes. The blood was then diluted in an isotonic saline solution (SSI) (1:1, v/v) and transferred to a tube that contained Ficoll-Histopaque solution (1:2, v/v) to form a density gradient. The sample was centrifuged at 1600 rpm for 30 minutes at 4°C. The gradient interphase, which contained the mononuclear cells, was collected, SSI cells were washed, and Trizol was added.
RNA isolation and RT-PCR: RNA extraction from the PBMCs was performed using Trizol, wherein a monophase phenol solution and guanidine isothiocyanate were used to lyse cells and dividing the sample into 2 phases: aqueous and organic. The aqueous phase was separated with chloroform, and RNA was precipitated with isopropanol. Genetic material was washed with alcohol and allowed to dry. RNA was resuspended with RNase- and DNase-free water. The index of purity of the RNA samples ranged between 1.8 and 2.0.
RNA samples were treated with DNase 1 (Invitrogen Life Technologies, CA, USA) to eliminate DNA contamination. Total RNA was used for the generation of cDNA and was performed from 1 µg of total RNA in a reaction volume of 20 µL containing 5X Buffer 5µL Retro-Transcriptase (Promega, WI, USA), 15 mM MgCl2, 1.25 ul 10 mM dNTP mix (Promega, WI, USA), 200 U M-MLV reverse transcriptase (Promega, WI, USA) and 1 µL of 10 mM OligodT (GE, UK). The reaction mixture was incubated for 60 minutes at 42°C in a thermocycler (Thermocycler Gradient, Eppendorf, Germany) and applied a final cycle of 90°C for 5 minutes.
The reverse-transcribed product (cDNA) was amplified by PCR in a final reaction volume of 25 µL containing 2 µL of cDNA, 1 mM deoxyribonucleotide dNTP Mix (Promega, WI, USA), 0.75 mM MgCl2, 2.5 mM oligonucleotide GoTaq and 1.25 units DNA polymerase (Promega, WI, USA). PCR was performed for 25 cycles, using a cycling program of 94°C for 1 minute, 60°C for 1 minute and 72°C for 1.30 minutes in a thermocycler for the amplification of 5-HTT and GAPDH. The oligonucleotides used for 5-HTT were: sense 5'-GAACTCCTGGAACAC TGGCAAC-3' and antisense 5'-ATGACAAATCCCGAAACGAAGC-3' (534 base pairs, [bp] product). In the case of GAPDH sequences of oligonucleotides used were: sense 5'-TGGGGAAGGTGAAGGTC GGAGTC-3' and antisense 5'-GACTTCAACAGCGACACCCACTC-3' (874 bp product). The amplicons were separated on an agarose gel and stained with ethidium bromide. The bands were analyzed by computerized densitometry. The optical density values for 5-HTT were calculated as the quotient between the values for 5-HTT and GADPH, expressed as the mean ± standard deviation.
Statistic analysis was performed using the Shapiro-Wilk homogeneity test and nonparametric Mann-Whitney test. Differences were considered statistically significant when p≤0.05.
Results: 5-HTT levels were nondetectable (ND) in patient with comorbid alcoholdependence and major depressive disorder. By Shapiro Wilk test, healthy volunteers and alcohol-dependent patients did not differ. Healthy volunteers expressed higher levels of 5-HTT gene (0.5012 ± 0.1349) compared with alcohol-dependent patients (0.3150 ± 0.1836) (p ‹ 0.0036, Mann-Whitney).
Discussion: Our PCR method allowed us to determine that 5-HTT expression is lower in the two groups of patients compared with healthy volunteers. These results are consistent with studies that have reported that 5-HTT expression declines in lymphocytes from major depression disorder patients compared with healthy volunteers. The lack of detection of 5- HTT in alcohol- dependence depressed patients suggests that this comorbidity leads to alterations in the expression of this 5-HTT.
Finally, our work is the first preliminary study that characterizes 5-HTT expression in the Mexican population, comparing alcohol dependence patients and patients with comorbid alcohol-dependence and major depression.


REFERENCES

  1. World Health Organization. Global Status Report on Alcohol 2004. Switzerland: Singapore Press; 2004.

  2. Fleiz C, Borges G, Rojas E, Benjet C et al. Uso de alcohol, tabaco y drogas en población mexicana, un estudio de cohortes. Salud Mental 2007;30:63-73.

  3. Consejo Nacional Contra las Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente, Instituto Nacional de Salud Pública, Fundación Gonzalo del Rio Aronte IAP. Encuesta Nacional de Adicciones 2008. México; 2009.

  4. Yaldizli O, Kuhl HC, Graf M, Wiesbeck GA et al. Risk factors for suicide attempts in patients with alcohol dependence or abuse and a history of depressive symptoms: a subgroup analysis from the WHO/ISBRA study. Drug Alcohol Rev 2010;29:64-74.

  5. Kandel ER, Schwartz JH, Jessell TM. Principles of neural science. Cuatra edición. USA: United Satates of America Press; 2000.

  6. Vengeliene V, Bilbao A, Molander A, Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 2008; 154:299-315.

  7. Heinz A, Goldman D, Gallinat J, Schumann G et al. Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. Psychopharmacology (Berl) 2004;174:561-570.

  8. Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs 2004;18:1105-1118.

  9. Naranjo CA, Chu AY, Tremblay LK. Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction. Neurotox Res 2002;4:343-361.

  10. Pivac N, Muck-Seler D, Mustapic M, Nenadic-Sviglin K et al. Platelet serotonin concentration in alcoholic subjects. Life Sci 2004;76:521-531.

  11. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci 2002;5(Suppl):1068-1070.

  12. Roy A, Bissette G, Nemeroff CB, DeJong J et al Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls. Biol Psychiatry 1990;28:767-772.

  13. Williams W, Reimold M, Kerich M, Hommer D et al Glucose utilization in the medial prefrontal cortex correlates with serotonin turnover rate and clinical depression in alcoholics. Psychiatry Res 2004;132:219-224.

  14. Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry 2008;13:131-146.

  15. Moussas G, Christodoulou C, Douzenis A. A short review on the aetiology and pathophysiology of alcoholism. Ann Gen Psychiatry 2009;8:10.

  16. Ehlers CL, Gizer IR, Vieten C, Gilder A et al Age at regular drinking, clinical course, and heritability of alcohol dependence in the San Francisco family study: a gender analysis. Am J Addict 2010;19:101-110.

  17. Stacey D, Clarke TK, Schumann G. The genetics of alcoholism. Curr Psychiatry Rep 2009;11:364-369.

  18. Wurtman RJ. Genes, stress, and depression. Metabolism 2005;54:16-19.

  19. Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: review of current literature. Neuro Endocrinol Lett 2010;31:4-10.

  20. Teicher MH, Andersen SL, Polcari A, Anderson CM et al. The neurobiological consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev 2003;27:33-44.

  21. Hariri AR, Holmes A. Genetics of emotional regulation: the role of the serotonin transporter in neural function. Trends Cogn Sci 2006;10:182-191.

  22. Boyce-Rustay JM, Wiedholz LM, Millstein RA, Carroll J et al. Ethanolrelated behaviors in serotonin transporter knockout mice. Alcohol Clin Exp Res 2006;30:1957-1965.

  23. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-705.

  24. Moak DH, Anton RF, Latham PK, Voronin KE et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebocontrolled trial. J Clin Psychopharmacol 2003;23:553-562.

  25. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987;41:266-274.

  26. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990;47:490-498.

  27. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 1992;51:729-739.

  28. Roy-Byrne PP, Pages KP, Russo JE, Jaffe C et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:129-136.

  29. Lima L, Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol 2002;22:797-804.

  30. Sheng M, Kim MJ. Postsynaptic signaling and plasticity machanisms. Science 2002;298:797-780.

  31. Vicente-Manzanares M, Sánchez-Madrid F. Role of the cytoskeleton during leucocyte responses. Nat Rev Immuol 2004;4:110-122.

  32. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008;8:460-471.

  33. Faraj BA, Olkowski ZL, Jackso RT. Prevalence of high serotonin uptakein in limphocytes of abstinent alcoholics. Biochem Pharmacol 1997;53:53-57.

  34. Rausch JL, Monteiro MG, Schuckit MA. Platelet serotonin uptake in men with family histories of alcoholism. Neuropsychopharmacology 1991;4:83-86.

  35. Heinze G. Mini International Neuropsychiatric Interview. Sheehan DV, Lecrubier Y (eds.). Spanish South and Central America version/DSMIV; 2000.

  36. Solis L, Cordero M, Cordero R, Martínez M. Caracterización del nivel de dependencia al alcohol entre habitantes de la Ciudad de México. Salud Mental 2007;30:62-68.

  37. Rio DC, Ares M Jr, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). New York: Cold Spring Harbor Laboratory Presss; 2010; p.5439.

  38. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005;21:389-395.

  39. Stamova BS, Apperson M, Walker WL. Identification and validation of suitable endogenous reference genes for gene expression studies in human peripheral blood. BMC Med Genomics 2009;2:49.

  40. Ross R, Kumpf K, Reske-Kunz AB. PCR-amplified cDNA probes for verification of differentially expressed genes. Biotechniques 1997;22:894-897.

  41. Yang GB, Qiu CL, Aye P, Shao Y et al. Expression of serotonin transporters by peripheral blood mononuclear cells of rhesus monkeys (Macaca mulatta). Cell Immunol 2007;248:69-76.

  42. Latvala J, Parkkila S, Niemela O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res 2004;28:619-624.

  43. Heinz A, Ragan P, Jones DW, Hommer D et al Reduced central serotonin transporters in alcoholism. Am J Psychiatry 1998;155:1544-1549.

  44. Tsao CW, Lin YS, Chen CC, Bai CH et al. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:899-905.

  45. Greenberg BD, Tolliver TJ, Huang SJ, Li Q et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999;88:83-87.

  46. Kranzler H, Lappalainen J, Nellissery M, Gelernter J. Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcohol Clin Exp Res 2002;26:1330-1335.

  47. Lesch KP, Bengel D, Heils A, Sabol SZ et al Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.

  48. Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. Am J Addict 2003;12(Suppl 1):S26-S40.

  49. Javors M, Tiouririne M, Prihoda T. Platelet serotonin uptake is higher in early-onset than in late-onset alcoholics. Alcohol Alcohol 2000;35:390-393.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Salud Mental. 2011;34